Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic bone formation with weekly PTH administration in ovariectomized rats.

Sébastien A Gittens1, Gregory R Wohl, Ronald F Zernicke

  • 1Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada

Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques
|May 18, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preliminary insights on high-fidelity embalming solutions for surgical skills training-An evaluation using the McMaster Embalming Scale and mechanical tests.

Anatomical sciences education·2026
Same author

Technology for Nucleic Acid Delivery in the Treatment of Hematological Malignancies.

Advanced drug delivery reviews·2026
Same author

Suppressing t(4;11) Acute Leukemia by Lipopolymer Nanoparticle Delivery of siRNA Targeting KMT2A::AFF1 with Enhanced Extrahepatic Delivery.

Advanced healthcare materials·2025
Same author

Editorial: Optimal physical activity across the lifespan for people of all abilities.

Frontiers in sports and active living·2025
Same author

Evaluating InPACT Intervention-Context Fit in Resource-Limited School Districts in Central Michigan.

The Journal of school health·2025
Same author

Engineering Lipid-Polymer Nanoparticles for siRNA Delivery to Cancer Cells.

Pharmaceuticals (Basel, Switzerland)·2025

Weekly administration of human parathyroid hormone (1-34) [PTH (1-34)] at 10 microg/kg significantly increased bone mineral density and bone volume in ovariectomized rats. This low dose demonstrated a net anabolic effect on skeletal tissue.

Area of Science:

  • Endocrinology
  • Bone Biology
  • Pharmacology

Background:

  • Osteoporosis is a significant health concern, particularly in postmenopausal women, leading to increased fracture risk.
  • Ovariectomized (OVX) animal models are widely used to study bone loss and test potential anabolic therapies.
  • Human parathyroid hormone (1-34) [PTH (1-34)] is a known anabolic agent for bone, but optimal dosing for systemic bone formation requires further investigation.

Purpose of the Study:

  • To compare the efficacy of different weekly subcutaneous doses of human parathyroid hormone (1-34) [PTH (1-34)] in promoting systemic bone formation.
  • To evaluate the anabolic potential of a low dose (10 microg/kg) of PTH (1-34) in a rat model of osteoporosis.

Main Methods:

  • Nine-month-old ovariectomized (OVX) Sprague-Dawley rats were treated weekly with vehicle, 10 microg/kg, or 80 microg/kg of PTH (1-34) for 4 weeks.

Related Experiment Videos

  • Bone mineral density (BMD) was assessed using dual x-ray absorptiometry.
  • Bone microarchitecture was analyzed using micro-computed tomography (microCT) and ashing.

    • Main Results:

    • The 10 microg/kg dose of PTH (1-34) significantly increased femoral BMD compared to vehicle and the 80 microg/kg group (p<0.025).
    • MicroCT analysis revealed significant increases in bone volume fraction and trabecular thickness in the femoral neck of the 10 microg/kg group compared to baseline and other treatment groups.
    • The 80 microg/kg dose did not show a significant anabolic effect compared to the vehicle control.

    Conclusions:

    • Weekly administration of 10 microg/kg of PTH (1-34) is sufficient to significantly enhance systemic bone mineral density in OVX rats.
    • This study demonstrates that a low total dose of PTH (1-34) can induce a net anabolic effect on skeletal tissue, suggesting potential for optimized therapeutic strategies.
    • The findings highlight the dose-dependent anabolic response to PTH (1-34) and identify a potentially effective low-dose regimen for treating bone loss.